Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under IFRS)NEW

May 13, 2026

Company name: Mitsubishi Chemical Group Corporation Listing: Tokyo Stock Exchange

Scheduled date of annual general meeting of shareholders: June 24, 2026 Scheduled date to commence dividend payments: June 3, 2026 Scheduled date to file annual securities report: June 22, 2026 Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: Yes (for securities analysts and institutional investors)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2026 (from April 1, 2025 to March 31, 2026)
   1. Results of Operations:

      (Percentages indicate year-on-year changes.)

      	Sales Revenue		Core Operating Income		Operating income		Net income		Net income attributable to owners of the parent		Comprehensive Income
      Fiscal year ended March 31, 2026 March 31, 2025	3,703,988 3,947,566	% (6.2) (10.0)	225,002 228,839	% (1.7) 10.0	30,078 141,550	% (78.8) (45.9)	78,425 105,636	% (25.8) (40.8)	11,829 45,020	% (73.7) (62.4)	251,905 77,464	% 225.2 (78.7)
      	Basic earnings per share			Diluted earnings per share		Return on equity attributable to owners of parent		Ratio of income before tax to total assets		Ratio of core operating income to sales revenue
      Fiscal year ended March 31, 2026 March 31, 2025	Yen 8.63 31.64			Yen 8.63 31.64		% 0.7 2.6		% 0.0 1.7		% 6.1 5.8

      Reference: Share of profit (loss) of associates and joint ventures Fiscal year ended March 31, 2026: ¥ (2,255) million Fiscal year ended March 31, 2025: ¥7,836 million Income before taxes

      Fiscal year ended March 31, 2026: ¥711 million ((99.3)%)

      Fiscal year ended March 31, 2025: ¥99,248 million ((58.7)%)

      (Note1) Core operating income is calculated as operating income excluding certain gains and expenses attributable to non-recurring factors. (Note2) Upon the approval at MCG's Ordinary General Meeting of Shareholders held on June 25, 2025 with regard to the absorption-type split

      agreement to transfer all shares and related assets of Mitsubishi Tanabe Pharma Corporation (hereinafter "MTPC"), which had been MCG's consolidated subsidiary, MTPC and its subsidiaries and affiliates have been transferred on July 1, 2025. MTPC and its subsidiaries and affiliates have been classified as discontinued operations, and sales revenue, core operating income, operating income, share of profit (loss) of associates and joint ventures, and income before taxes for the current fiscal year and the previous fiscal year represent the amounts of continued operations excluding discontinued operations.

      Mitsubishi Tanabe Pharma Corporation changed its corporate name to Tanabe Pharma Corporation as of December 1, 2025.

   2. Financial Position:

      	Total assets	Total equity	Equity attributable to owners of the parent	Ratio of equity attributable to owners of parent to total assets	Equity attributable to owners of the parent per share
      Fiscal year ended				%	Yen
      March 31, 2026	5,876,609	2,414,680	1,761,675	30.0	1,296.73
      March 31, 2025	5,894,619	2,284,569	1,740,570	29.5	1,223.01

   3. Cash Flows:

   	Net cash provided by (used in) operating activities	Net cash provided by (used in) investing activities	Net cash provided by (used in) financing activities	Cash and cash equivalents at end of the period
   Fiscal year ended
   March 31, 2026	436,287	124,470	(375,207)	527,104
   March 31, 2025	552,847	(275,434)	(246,654)	326,144

2. Cash dividends

   	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolid ated)	Ratio of dividends to equity attributable to owners of parent (Consolidated)
   	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
   Fiscal year ended	Yen	Yen	Yen	Yen	Yen		%	%
   March 31, 2025	-	16.00	-	16.00	32.00	45,595	101.2	2.6
   March 31, 2026	-	16.00	-	16.00	32.00	43,521	370.8	2.5
   March 31, 2027 (Forecast)	-	16.00	-	16.00	32.00		34.2

3. Prospects for the Following Fiscal Year

   (Percentages indicate changes in comparison with the same period of the previous fiscal year)

   	Sales Revenue		Core Operating Income		Operating income		Net income		Net income attributable to owners of the parent		Basic earnings per share
   		%		%		%		%		%	Yen
   First Half of FY2026	1,861,000	3.4	139,000	10.2	143,000	65.3	98,000	(31.2)	59,000	(46.4)	43.43
   FY2026	3,800,000	2.6	305,000	35.6	300,000	897.4	200,000	155.0	127,000	973.6	93.48

   Reference: Income before taxes

   First Half of FY2026: ¥129,000 million(87.7%), FY2026: ¥270,000 million(－%)

   * Notes

   1. Significant changes in the scope of consolidation during the period : Yes

      Newly included: 2 (Company Name) Coregas Pty Ltd, Esteve Teijin Healthcare, S.L. (current name: Nippon Sanso Homecare Espana, S.L.U.)

      Excluded: 7 (Company Name) Mitsubishi Tanabe Pharma Corporation (current name: Tanabe Pharma Corporation), Mitsubishi Tanabe Pharma Factory Ltd. (current name: Tanabe Pharma Factory Co., Ltd.), Mitsubishi Tanabe Pharma America, Inc. (current name: Tanabe Pharma America, Inc.), Alpha Therapeutic Corporation, Welfide International Corporation, Medicago Inc., J-

      Flim Corporation

   2. Changes in accounting policies and changes in accounting estimates

      1. Changes in accounting policies required by IFRS : None

      2. Changes in accounting policies due to other reasons : None

      3. Changes in accounting estimates : None

   3. Number of issued shares (ordinary shares)

      1. Total number of issued shares at the end of the period (including treasury shares)

         As of March 31, 2026

         1,441,467,207 Shares

         As of March 31, 2025

         1,506,288,107 Shares

      2. Number of treasury shares at the end of the period

         As of March 31, 2026

         82,919,774 Shares

         As of March 31, 2025

         83,102,073 Shares

      3. Weighted-average number of shares outstanding during the period

*Mitsubishi Chemical Group Corporation adopted a performance-based share compensation plan that uses executive compensation Board Incentive Plan (BIP) trusts. Mitsubishi Chemical Group Corporation stocks held by BIP trust are included in treasury shares.

(Reference)

Number of Company's shares in executive compensation BIP trust:

Disclosure regarding audit procedures

Financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.

Proper use of earnings forecasts, and other special matters

*The forward-looking statements are based largely on the Company's expectations and information available as of the date hereof, and are subject to risks and uncertainties which may be beyond the Company's control. Actual results could differ materially due to numerous factors. The Company's stance on forward-looking statements is described on pages [5] hereof.

*This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

1. Qualitative Information on Financial Results for the Term

(Supplemental materials) Trends in Management Indicators

―1-

During the consolidated fiscal year under review (April 1, 2025 to March 31, 2026; the same applies hereinafter), the global economy saw the impact of US trade policies spread to various regions worldwide. The global economy nevertheless maintained generally solid growth, buoyed by robust US consumer spending, capital investment stemming from AI-related demand, and capital investment driven by improving corporate earnings and a recovery in personal consumption due to the improving employment and income environment in Japan, as well as by China's economic stimulus measures and stable personal consumption supported by a robust employment environment in Europe. Since March 2026, however, the outlook has remained uncertain due to rising geopolitical risks in the Middle East and elsewhere that have led to surging prices for certain raw materials and fuels.

Against this backdrop, compared to the previous consolidated fiscal year (April 1, 2024 - March 31, 2025; same hereafter), sales revenue of the Mitsubishi Chemical Group (the MCG Group) decreased ¥243.6 billion, or 6.2% to

¥3,704.0 billion. In the profit front, core operating income declined ¥3.8 billion, or 1.7%, to ¥225.0 billion. Meanwhile, operating income was down ¥111.5 billion, or 78.8%, to ¥30.1 billion. Income before taxes decreased ¥98.5 billion, or 99.3%, to ¥0.7 billion. Net income attributable to owners of the parent dropped ¥33.2 billion, or 73.7% to ¥11.8 billion.

The overview of financial results by business segment for the consolidated fiscal year ended 2025 is shown below. Segment gains or losses are stated as core operating income, which excludes gains or losses from non-recurring factors such as losses from business withdrawals, streamlining, and other factors.

In comparison with the previous fiscal year, sales revenue decreased ¥11.7 billion, to ¥1,059.6 billion and core operating income rose ¥8.4 billion, to ¥32.3 billion.

In the Advanced Films & Polymers sub-segment, selling prices were maintained or increased, but revenue declined due to the transfer of shares in J-Film Corporation and the transfer of the triacetate fiber and other businesses, as well as the impact of customer inventory adjustments reflecting a decline in demand for display applications from the strong demand seen in the previous fiscal year.

In the Advanced Solutions sub-segment, too, selling prices for a variety of products were maintained or raised, but revenue fell due to the transfer of shares in certain subsidiaries, a decrease in sales volume resulting from waning demand for EV applications in Europe and the United States, and a decline in sales volume for housing and construction materials, primarily in the domestic market.

In the Advanced Composites & Shapes sub-segment, sales volume dropped due to the partial suspension of general-purpose firing lines in the carbon fiber business, but revenue was up due to rising demand for high-performance engineering plastics-primarily for semiconductor manufacturing equipment-as well as expanded sales of carbon fiber composite parts and favorable foreign exchange effects.

Core operating income in this segment increased despite the recognition of an impairment loss on Soarnol-related fixed assets in the UK and cost increases due to inflation and other factors. This increase was due to the absence of the impairment losses on production facilities and intangible assets at Gelest, Inc. in the current fiscal year, an improvement in gross margins resulting from higher selling prices across semiconductor-related and other businesses, greater demand for high-performance engineering plastics-primarily for use in semiconductor manufacturing equipment-and higher sales of carbon fiber composite parts, and rationalization effects resulting from the revamping of production sites across numerous businesses.

―2-